Urinary products maker Rochester Medical last week agreed to be acquired by an affiliate of C.R. Bard Inc. of Murray Hill, N.J., for about $262 million. On Aug. 19, Bard also agreed to acquire Brooklyn Center-based Medafor, which makes blood clot treatments, for $200 million in cash and as much as $80 million more depending on milestones reached.
On the Rochester Medical deal, Feltl and Co. analyst Matt Weight wrote: “This merger makes sense on several fronts. Most notably we believe Rochester Medical maintains industry-leading technology, specifically within its intermittent catheter business … This merger likely will allow a substantial increase in sales efforts.”
SurModics, a provider of drug-delivery technologies, recently announced a restructuring that will trim the workforce by 6 percent and result in a one-time charge of about $500,000.
Analysts for Zachs Equity Research pointed out that this isn’t the first restructuring at the Eden Prairie company. SurModics had restructurings in 2011 and 2010. Of the most recent restructuring, Zachs analysts wrote: “We are positive on the steps taken by SurModics to increase efficiencies.”